Anebulo Pharmaceuticals Ownership
| ANEB Stock | USD 2.05 0.02 0.99% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Anebulo |
Anebulo Stock Ownership Analysis
About 65.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.37. Anebulo Pharmaceuticals had not issued any dividends in recent years. Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. The company was incorporated in 2020 and is based in Lakeway, Texas. Anebulo Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people. For more info on Anebulo Pharmaceuticals please contact Richard Cunningham at (512) 598-0931 or go to https://www.anebulo.com.Besides selling stocks to institutional investors, Anebulo Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Anebulo Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Anebulo Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Anebulo Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
About 65.0% of Anebulo Pharmaceuticals are currently held by insiders. Unlike Anebulo Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Anebulo Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Anebulo Pharmaceuticals' insider trades
Anebulo Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Anebulo Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Anebulo Pharmaceuticals backward and forwards among themselves. Anebulo Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Anebulo Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-03-31 | 144 | Wells Fargo & Co | 2024-03-31 | 62.0 | Royal Bank Of Canada | 2024-03-31 | 38.0 | Jpmorgan Chase & Co | 2024-03-31 | 9.0 | Adar1 Capital Management Llc | 2024-03-31 | 0.0 | Landscape Capital Management,llc | 2024-03-31 | 0.0 | Praetorian Pr Llc | 2023-12-31 | 0.0 | Mangrove Partners | 2023-12-31 | 0.0 | Bank Of America Corp | 2024-03-31 | 0.0 | 22nw, Lp | 2024-03-31 | 5.4 M | Lvw Advisors, Llc | 2024-03-31 | 642 K |
Anebulo Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Anebulo Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Anebulo Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Anebulo Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aryeh Jason few days ago Acquisition by Aryeh Jason of 2482 shares of Anebulo Pharmaceuticals at 2.1 subject to Rule 16b-3 | ||
22nw Fund, Lp over three weeks ago Acquisition by 22nw Fund, Lp of 1703577 shares of Anebulo Pharmaceuticals at 0.125 subject to Rule 16b-3 | ||
Kenneth Cundy over three months ago Acquisition by Kenneth Cundy of 72613 shares of Anebulo Pharmaceuticals subject to Rule 16b-3 | ||
Kenneth Cundy over three months ago Acquisition by Kenneth Cundy of 72613 shares of Anebulo Pharmaceuticals at 2.78 subject to Rule 16b-3 | ||
English Aron R over six months ago Acquisition by English Aron R of 300000 shares of Anebulo Pharmaceuticals subject to Rule 16b-3 | ||
Cunningham Richard Anthony over six months ago Acquisition by Cunningham Richard Anthony of 600000 shares of Anebulo Pharmaceuticals subject to Rule 16b-3 | ||
Shah Bimal R over six months ago Acquisition by Shah Bimal R of 26097 shares of Anebulo Pharmaceuticals subject to Rule 16b-3 |
Anebulo Pharmaceuticals Corporate Filings
8K | 17th of June 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 8th of March 2024 Other Reports | ViewVerify | |
F4 | 1st of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 14th of November 2023 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Anebulo Stock
When determining whether Anebulo Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Anebulo Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anebulo Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anebulo Pharmaceuticals Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anebulo Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anebulo Pharmaceuticals. If investors know Anebulo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anebulo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Return On Assets (0.58) | Return On Equity (1.04) |
The market value of Anebulo Pharmaceuticals is measured differently than its book value, which is the value of Anebulo that is recorded on the company's balance sheet. Investors also form their own opinion of Anebulo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Anebulo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anebulo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Anebulo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anebulo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anebulo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anebulo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.